Samsung Biologics today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.
| - Samsung Biologics to develop and manufacture antibody for ADC candidate - Latest deal comes as Samsung Biologics is on track to complete construction of an ADC facility this year INCHEON, South Korea, Feb. 7, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs. Under the terms of the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences’ ADC program designed to treat solid tumors. LegoChem Biosciences aims to submit an Investigational New Drug application to the U.S. FDA in the first half of 2025, with non-clinical data showing promising efficacy results. The company is also on track to adding ADC to its pipeline, with the construction of a standalone, dedicated ADC facility expected to be operational within 2024. “Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients,” said John Rim, CEO and President of Samsung Biologics. “We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.” “LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract,” said Yong-Zu Kim, CEO and President of LegoChem Biosciences. Samsung Biologics will offer comprehensive services for ADC development and manufacturing, building on its expertise and capacity in antibody engineering, process development, and large-scale manufacturing of antibodies. The company has also been making active investments through the Samsung Life Science Fund in biotech companies pioneering ADC linker technologies and toolbox. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics completed Bio Campus I with Plant 4, offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 180KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Samsung Biologics Media Contact About LegoChem Biosciences, Inc. LegoChem Biosciences (KOSDAQ: 141080) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on researching and developing Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics, and anti-fibrotic based on proprietary platform technologies. For more information, visit LegoChem Biosciences, Inc. at https://www.legochembio.com/index.php?lang=e LegoChem Biosciences Media Contact
SOURCE Samsung Biologics | ||
Company Codes: Korea:207940 |
View original content:
